Comparative Pharmacology
Head-to-head clinical analysis: MICROSUL versus RENOQUID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROSUL versus RENOQUID.
MICROSUL vs RENOQUID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
RENOQUID is a combination of sulfamethoxazole, an intermediate-acting sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits sequential steps in bacterial folic acid synthesis: sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
Terminal elimination half-life is 2.5 hours (range 2–3 hours) in patients with normal renal function. In renal impairment (CrCl <30 mL/min), half-life may extend to 8–12 hours.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Renal excretion accounts for approximately 70% of elimination, with 30% excreted unchanged in urine. Biliary/fecal excretion accounts for 30%, primarily as metabolites.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic